Narwani V, Torabi SJ, Kasle DA, et al. - Since corticosteroid-eluting stents (CESs) are increasingly used after endoscopic sinus surgery to lessen the need for revision surgery, but their use is not without risks, researchers conducted this retrospective cross-sectional study to describe adverse events related to CESs. The MAUDE database was searched for reports of adverse events involving the use of CESs approved by the Food and Drug Administration such as Propel, Propel Mini, Propel Contour, and Sinuva (Intersect ENT). Postoperative infection, including multiple cases of fungal infection, was the most commonly reported adverse event, followed by stent migration. An increased understanding of the complications associated with CESs can be used to better inform both patients during the consenting process and surgeons in their surgical decision making.